A Randomized Multicenter Trial of Neoadjuvant Taxotere (T) and Adriamycin/Cytoxan (Ac): A Validation.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2017
At a glance
- Drugs Docetaxel (Primary) ; Cyclophosphamide; Doxorubicin
- Indications Breast cancer
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms TACAC
- 26 Aug 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Oct 2016.
- 23 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 28 Jul 2015 Planned End Date changed from 1 Sep 2016 to 1 Sep 2017 as per ClinicalTrials.gov record.